1.
Background 
Societal burden of alcohol abuse and dependence
Approximately half of all Americans have at least one relative with an alcohol use disorders (AUD), with some of these individuals having this trait across multiple generations (Research Society on Alcoholism [RSA], 2011 [RSA], , 2015 . Half of individuals meeting a lifetime diagnosis for an AUD do so by age 21 with two-thirds doing so by age 25 (Hingson et al., 2006) . This is especially troubling given between 15% and 25% of individuals in the military have AUDs (Bray and Hourani, 2007; Bray et al., 2006; RSA, 2011; . There has been a narrowing of the gender gap recently, especially among youth and the elderly (Brienza and Stein, 2002; Nelson et al., 1998 ; Substance Abuse and Mental Health Services Administration (SAMHSA), 2012; Wilsnack et al., 1991) . In the US, the cost of AUDs approaches a quarter of a trillion dollars each year (Harwood et al., 2000; RSA, 2015) , with close to 100,000 people dying due to alcohol-related causes every year (RSA, 2011; . The Centers for Disease Control and Prevention (CDC) considers AUDs the third leading cause of preventable death (Mokdad et al., 2004) and is a major factor in the top three leading medical causes of death (RSA, 2011; . Moreover, a direct association has been found between alcohol (ethanol, the primary form of alcohol abused, will be used instead of alcohol in the rest of the paper) use and 50 different medical conditions (Reed et al., 1996; Rehm et al., 2003) .
(Endo)Phenotypic associations with ethanol abuse and dependence
For the present discussion, an endophenotype (sometimes called intermediate phenotype) is defined as a characteristic (a) having relative specificity for the psychiatric disorder being studied, (b) a trait vs state characteristic such that it predates overt expression of symptoms, (c) having significant heritability and is associated with familial density of the disorder, and (d) has biological and clinical plausibility (e.g., Ray and Heilig, 2013) . Preclinical and clinical research indicates the following endophenotypes are directly related to the development of ethanol dependence (a) lower initial sensitivity to ethanol's aversive effects (c.f., Bell et al., 2006b Bell et al., , 2012 Colombo et al., 2006; Draski and Deitrich, 1996; Le et al., 2001b; Schuckit and Gold, 1988) , (b) greater levels and/or quicker development of ethanol-induced tolerance (c.f., Costin and Miles, 2014; Lê and Mayer, 1996) , (c) anxiety-like and/or depressive behavior including during ethanol withdrawal (c.f., Ciccocioppo et al., 2006; Heilig et al., 2010; Kirby et al., 2011; Overstreet et al., 2006; Pautassi et al., 2010; Sjoerds et al., 2014; Thorsell, 2010) , (d) stress reactivity (c.f., Barr and Goldman, 2006) , and (e) sweet liking/preference (c.f., de Wit and Richards, 2004; Kampov-Polevoy et al., 2014; Lange et al., 2010; Pepino and Mennella, 2007; Perry and Carroll et al., 2008) .
Endophenotypes also include ethanol-associated physiological and behavioral stimulation (Trim et al., 2010) [which is modeled in rodents by increased motor activity and/or approach behavior (Chappell and Weiner, 2008; Faria et al., 2008; Wise and Bozarth, 1987) , aggression (Chiavegatto et al., 2010) , and social facilitation Spear, 2009, 2010) ]. Interestingly, there appears to be pharmacological validity for ethanol-associated stimulation as well as reward, with histaminergic (Panula and Nuutinen, 2011 and references therein) and ghrelin (Jerlhag et al., 2011 and references therein) systems implicated in ethanol-induced motor activation, ethanol-induced conditioned place preference, ethanol-preference and excessive ethanol intake. Nevertheless, there are concerns with establishing consilience and translatability of ethanol-induced stimulation between the preclinical and clinical literature. For instance, other than lower dose effects on self-report (Morzorati et al., 2002; Viken et al., 2003) , heart rate (Finn and Justus, 1997; Peterson et al., 1996) , and brain activity (Lukas et al., 1986; Sorbel et al., 1996; Trim et al., 2010 ) the stimulating effects of ethanol are not as readily seen in humans compared with rodents.
Binge drinking as a developmental phenomenon
Clinical evidence indicates that binge drinking behavior is engaged by adolescents and young adults more often and to a greater magnitude than older (>24 years old) adults (c.f., Courtney and Polich, 2009; Marczinski et al., 2009; Martinic and Measham, 2008; Plant and Plant, 2006) . Earlier studies reporting contrary findings may be due to changes in the definition of binge drinking over time. The fact that binge ethanol drinking occurs mostly in adolescents and young adults is due, at least in part, to the fact that younger subjects are less affected by ethanol than older individuals. Most of the literature evaluating this observation has been done in rodent models (see discussion by Spear, 2010) , with some evidence for this from clinical observations as well. The most obvious clinical observation is that adolescents tend to drink substantially more ethanol per occasion than adults (NIAAA, 2012; SAMHSA, 2012) even though they can achieve similar BACs with fewer drinks (Donovan, 2009; NIAAA, 2012; SAMHSA, 2012) . Regarding insensitivity to ethanol's effects, Rohsenow et al. (2012) found that hangover insensitivity was significantly correlated with intoxication insensitivity and future ethanol-related problems. Another recent study (Gilman et al., 2012) examined the effects of ethanol in heavy and light social drinkers. The study examined individual subjective and objective, the latter measured by fMRI to emotional stimuli, responses while BACs were clamped at 80 mg%. These authors reported that heavy, relative to light, drinking individuals had both reduced sensitivity to ethanol's subjective effects and reduced activation of the nucleus accumbens (Acb) and amygdala (Amyg) to emotional stimuli.
There also is evidence suggesting that young heavy drinkers, relative to young light drinkers, experience greater stimulation on the rising limb of the BAC-curve and lower sedation on the descending limb of the BAC-curve (e.g., Holdstock et al., 2000; King et al., 2002) . King et al. (2011) replicated their previous findings that weekly binge drinkers experience greater stimulation and less sedation following ethanol consumption than young light drinkers. These authors also reported that greater stimulation and lower sedation predicted escalated binge drinking over the next 2 years. In turn, escalated binge drinking predicted an increased likelihood of meeting diagnostic criteria for an AUD (King et al., 2011) . This parallels findings that Family History Positive (FHP) for AUD individuals experience greater stimulation on the ascending limb and less sedation on the descending limb of the BAC-curve than family history negative (FHN) for AUD controls (e.g., Brunelle et al., 2004 Brunelle et al., , 2007 Thomson, 1990, 1999; c.f., Sher, 1991; Windle and Searles, 1990) .
The difficulty with evaluating whether adolescent and young adult binge drinkers experience greater reward (e.g., stimulation) and less aversion (e.g., sedation) than light drinkers or older drinkers is the role of positive outcome expectancies from drinking to intoxication, such that young binge-drinkers expect increased peer affiliation as well as feelings of euphoria and excitement (c.f., Duka et al., 1998; Marczinski et al., 2009; Martinic and Measham, 2008; Plant and Plant, 2006) . Note that these are not expectancies associated with drinking in general but specifically "drinking to intoxication". This parallels the BAC requirement (greater than 0.08 gram percent; i.e., 80 mg%) found in NIAAA's definition of binge ethanol-drinking (NIAAA, 2004) . There is preclinical evidence (e.g., Bell et al., 2000 Bell et al., , 2001 indicating that ethanol-exposure approximating these BAC levels can induce tolerance to ethanol-induced motor impairment (i.e., ataxia). As noted in the discussion on the addiction process, escalation of intake is associated with tolerance to effects induced by ethanol which, in turn, may lead to abuse and dependence. However, as noted by (Ahmed, 2011) , escalation in ethanol drinking, or the intake of substances of abuse, does not necessarily stem from the development of neuronal tolerance in humans. Although, it also should be noted that these other possible explanations for the development of tolerance in humans (Ahmed, 2011) , such as social and economic factors, are not easily amenable to examination when using animal models.
Polysubstance abuse
As with ethanol, initiation of drug use and abuse generally occurs during adolescence and young adulthood (Kandel and Logan, 1984) . Moreover, abuse of one drug is positively associated with initiating use of another drug of abuse (Yamaguchi and Kandel, 1984) . Thus, again as with ethanol, the developmental periods of adolescence and young adulthood represent the peak times for initiating and using multiple substances of abuse (c.f., Dean et al., 2014) . A recent meta-analysis/literature review addressed whether respondent subclassifications of substance use could be determined from published studies on adolescent and young adults (Tomczyk et al., 2016) . Twenty-three studies (~a half million subjects) met inclusion criteria. Overall, these authors reported that none to low use were the largest "latent" classes, moderate to high single substance use (e.g., ethanol) were intermediate in size, and polysubstance use had the least respondents. However, approximately 32% of the respondents, across all of the analyzed studies, endorsed use of at least 2 substances, usually ethanol and smoking (Tomczyk et al., 2016) . Given the above, Connor et al. (2014) make some important points about diagnostic and research challenges as they relate to changes introduced by the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) (American Psychiatric Association, 2013) . In particular, the DSM-5 removed the diagnostic category "Polysubstance dependence" along with the terms "Abuse" and "Dependence". This may result in underestimating polysubstance dependence, since each drug class an individual abuses can be scaled separately on the severity index.
Stages in the development of alcohol use disorders
AUDs represent a chronic, progressive, relapsing disorder that advances from experimentation to dependence (Heilig and Egli, 2006; Jupp and Lawrence, 2010; Koob, 2009; Koob and Le Moal, 2008; Koob and Volkow, 2010; Spanagel, 2009; Volkow and Li, 2005) . During experimentation, the individual experiences the rewarding, euphoric and positive-reinforcing effects of ethanol consumption. Moreover, experimentation includes binge-like drinking and acute increases in motor, such as pro-social behavior, and autonomic, such as heart rate, activity which are generally perceived as euphoric and pleasant. The experimentation and binge-drinking stages are associated with positive reinforcement; which increases the probability, frequency and magnitude of subsequent drinking behavior. After chronic use, there is an increase in dysphoria (as opposed to euphoria), such as anxiety, during ethanol withdrawal. These dysphoric effects can be physiological in nature (e.g., hangover, hyperthermia, tachycardia, etc.) or associated with negative behavioral sequelae, such as getting arrested. With this increase in dysphoria, the individual often seeks to relieve this state by relapsing to ethanol drinking. Essentially, during the early stages of AUDs positive reinforcement predominates, whereas during later stages of AUDs negative reinforcement tends to predominate (Koob et al., 2014a (Koob et al., , 2014b Le Moal, 2006, 2008) .
Addiction-related positive-vs negative-reinforcement can also be characterized in terms of impulsive vs compulsive ethanol drinking (Garbusow et al., 2014; Hagele et al., 2014; Koob et al., 2014a Koob et al., , 2014b Le Moal, 2006, 2008; Spanagel, 2009) . Within these constructs, impulsive drinking is associated with binge drinking and intoxication, during which an individual putatively has some volitional control, and subsequently there is the maintenance of ethanol drinking (Gray and MacKillop, 2014; Hamilton et al., 2014 ; but see Irimia et al., 2013) . Chronic usage leads to the development of tolerance to ethanol's effects (Kippin, 2014) . Following the development of tolerance there is the development of dependence as indicated by withdrawal signs once ethanol use is terminated and chronic relapsing to mitigate associated dysphoria . This negative reinforcement to mitigate physical and behavioral withdrawal leads in turn to compulsive/habitual drinking (Koob, 2014; Potgieter et al., 1999) . It is during this transition from impulsive to compulsive drinking that the individual appears to "lose control" of their drinking. This, in turn, leads to a preoccupation with, and an anticipation of, future ethanol consumption during periods of acute and chronic ethanol withdrawal (Burnett et al., 2016; Koob et al., 2014a Koob et al., , 2014b Le Moal, 2006, 2008) . Nevertheless, it should be noted that AUDs do not necessarily progress in a linear fashion, such that the frequency and/or duration a person experiences these cycles of drinking, abstaining, seeking, and relapsing can differ substantially across individuals (e.g., Barker and Taylor, 2014; Mackenzie et al., 2014; Sartor et al., 2014; Van Rizen and Dishion, 2014 ).
Genetics of alcohol use disorders
The well-documented familial incidence of alcoholism as well as findings from twin and adoption studies indicate that ethanol dependence is a highly heritable disease (Cloninger, 1987; Cotton, 1979; Schuckit, 1986) . For instance, FHP individuals are at a 3e7 fold increased risk to develop alcoholism compared with FHN controls (Reich et al., 1998) . Furthermore, this genetic proposal has been micro-dissected by multiple gene studies [for example the Collaborative Study On the Genetics of Alcoholism (COGA), the Study of Addiction: Genes and Environment (SAGE) and the European research project on risk taking behavior in teenagers (IMAGEN)] examining the association between diagnostic criteria for ethanol dependence, or related phenotypes, and the presence of single nucleotide polymorphisms (SNPs) in ethanol-dependent individuals (Agrawal et al., 2008; Chen et al., 2012; Dick, 2013; Edenberg, 2012; Edenberg and Foroud, 2013; Enoch, 2013; Kapoor et al., 2013; Levey et al., 2014; MacKillop and Acker, 2013; Ray and Heilig, 2013; Rietschel and Treutlein, 2013; Wall et al., 2013; Wong and Schumann, 2008; Yan et al., 2014) .
Summary of human characteristics for animal model development
This first section provided an overview of characteristics observed in individuals suffering from AUDs and the second section of this paper will discuss how well selectively bred rats can display these same characteristics. It is clear that AUDs continue to be a major public health concern and despite some inroads made into identifying molecular targets for the treatment of ethanol dependence considerable more research is needed. Some of the key characteristics often displayed by individuals with AUDs include, an early onset of drinking, engaging in binge-like drinking, reduced sensitivity to the aversive and perhaps greater sensitivity to the stimulating effects of ethanol, the development of tolerance to ethanol's effects, anhedonia associated with ethanol withdrawal, increased stress reactivity, greater sweet-liking, pursuance of novelty-seeking, certain electrophysiological measures, and key gene and/or protein differences from controls. It is believed that an animal model of AUD should display many of these characteristics and as the number of characteristics observed increases so too does the face validity of the animal model.
Background from an animal model perspective

Pros and cons of animal model research
While drug development relies heavily on in vitro assays early in the process, subsequent studies in vivo are required in the pathway to FDA regulation and clinical use (Blass, 2015) . In vivo assays are required to evaluate a compound in a highly complex biological system as opposed to in vitro assays, which are constrained by their limited macromolecular environment (Blass, 2015) . Essentially, the outcome measures of an in vivo assay are greater than the sum of its multiple constituent measures or presumable endpoints initially measured using in vitro assays. The role of animals in research on human diseases continues to be debated (e.g., Cattaneo et al., 2015; Doke and Dhawale, 2015; Fiester, 2008; Gupta, 2014; Helms et al., 2015; . Regarding this debate, a major premise for arguments against animal research is the claim that no animal model recapitulates the entire disease state of humans, especially as it relates to psychiatric disorders (e.g., Hayes and Delgado, 2006 ; but see Humby and Wilkinson, 2006 for a discussion on examining endophenotypes/intermediate phenotypes as a compromise). The polygenic nature of mental health disorders (e.g., Nurnberger and Berrettini, 2012) indicates that often times psychiatric genetics and epidemiology must use endophenotypes to parse the genetics associated with symptomology of these disorders (Chen et al., 2012; MacKillop and Munafo, 2013) . Thus, the term intermediate phenotype, instead of endophenotype, is often used to convey that an observed genetic, behavioral or physiological characteristic bridges the gap between the disease process and diagnostic criteria. An example is prepulse inhibition (PPI) of the acoustic startle response (ASR) and schizophrenia. Rudimentary screening for the disorder doesn't include testing for altered PPI, yet preclinical PPI assays have strong predictive validity for detecting the efficacy of antipsychotics. These endophenotypes and biomarkers can be identified by findings from next generation RNA and/or DNA sequencing (Barrera and Sebat, 2016; Gupta and Gupta, 2014) , pharmacogenomics (Perlis, 2016) , gene networks (Parikshak and Geschwind, 2016) , and genetic epidemiology (Merikangas and Merikangas, 2016) . Two examples are the mu-opioid receptor (MOR) variant, OPRM1, and the long and short variants of the serotonin transporter (SERT) (Berretini, 2013; Johnson, 2004 Johnson, , 2010 Johnson et al., 2003) . More recent endophenotype identification has used advanced imaging techniques (Greicius, 2016; c.f., Self and Staley, 2010; Zahr and Peterson, 2016) or a combination of the above (e.g., Muller et al., 2010) . Thus, with an increased focus on precision medicine and progress in identifying endophenotypes animal models, especially those used to determine treatment efficacy, need to incorporate biomarkers associated with AUDs and their development (e.g., Heilig and Leggio, 2016; Kerwin and Arranz, 2002; Miczek, 2008; Millan, 2008; Winsky et al., 2008; Wong et al., 2010) .
Validity, reliability and reproducibility
By displaying characteristics observed in the clinical setting, animal models are considered to have significant validity (e.g., Egli et al., 2016; Heilig and Egli, 2006; Litten et al., 2012) . In basic terms, validity refers to the ability of an experimental method or measurement to accurately and precisely portray the construct, being examined, under "real-world" conditions. The three primary constructs of validity pertaining to medications discovery or screening are internal, external, and predictive validity. A test or method is considered to have internal validity if the causal inferences that Factor A influences Factor B observed in the test or method are appropriate. This generally requires (1) Factor A preceding Factor B, (2) there is a significant association between Factor A and Factor B, and (3) the results obtained are not due to confounding factors. A number of confounding factors interfere with internal validity including variable selection, repeated testing, instrumentation (i.e., test equipment), sample selection bias, statistical regression to the mean, attrition of subjects, etc. External validity is the generalizability of findings from a test or method across situations and/or across subjects/samples, which requires efforts to limit multiple types of selection bias. Thus, replication is the best confirmation of external validity with meta-analytic techniques serving a similar purpose. Predictive validity, as it relates to animal models for drug discovery and screening, refers to the ability of a method or test (i.e., animal model) to correctly identify medications that interfere with the development and/or expression of AUDs.
It is important to recognize that, when pursuing the identification of medications to treat mental health disorders, deficits in external or face validity do not necessarily negate predictive validity. For instance, the Porsolt forced swim test and PPI of ASR have high predictive validity for medications to treat depression and schizophrenia, yet have poor face validity for these disorders. Finally, reliability refers to consistency of findings across experiments, such that the relevance of a model is determined by experimental reliability and extrapolation reliability (e.g., Rohra and Qazi, 2008) . The former refers, essentially, to test-retest reliability such that the model will yield similar results across multiple tests, while controlling for within-subject effects. The latter refers to the ability of an animal model to yield results similar to those found in the clinical population. However, experimental and extrapolation reliability are based implicitly on the presence of sound validity. Thus, if a model has high reliability but low validity then the model will have minimal relevance.
Animal models
Animal models attempt to parallel the human condition and many of these models have provided important information about mediating factors for medical and psychiatric disorders (c.f., Adan and Kaye, 2011; Buccafusco, 2001; Conn, 2008; Griffin, 2002; Kalueff, 2006; Kobeissy, 2012; McArthur and Borsini, 2008a,b,c; McKinney, 1988 McKinney, , 2001 Pankevich et al., 2013; Siegel, 2005; Verma and Singh, 2014; Warnick and Kalueff, 2010) , including dual-diagnosis (Edwards and Koob, 2012) . Particularly germane to the present topic, animal models have led to important findings on neural substrates mediating addiction to multiple substances of abuse (c.f., De Biasi, 2015; Dwoskin, 2014; Paulus, 2016a, 2016b; Frascella et al., 2011; Heidbreder, 2008; Koob et al., 2014a; McArthur and Borsini, 2008c; Nader, 2016; Olmstead, 2011) and ethanol in particular (Bell et al., , 2006b (Bell et al., , 2013 Ciccocioppo, 2013; Crabbe et al., 2013; Knapp and Breese, 2012; Maldonado-Devincci et al., 2012; McBride and Li, 1998; McBride et al., 2014b; Ramsden, 2015; Ryabinin, 2012) . As indicated above, advanced neuroimaging techniques including resting state functional connectivity are being used to develop endophenotypes for medications development targeting AUDs (e.g., Brown et al., 2015; Cui et al., 2015; Ernst et al., 2015; Fedota and Stein, 2015; Gowin et al., 2015; Gullo et al., 2011; Moeller et al., 2016; Muller-Oehring et al., 2015a Schuckit et al., 2016; Squeglia et al., 2014) . In general, an animal model has the advantage of allowing the experimenter to control factors such as the animal's genetic background, environment, and drug exposure. In addition, an animal model allows for the examination of neurobehavioral, neurochemical and neurophysiological correlates associated with the behavioral, physiological and/or neurological state that is modeled. These correlates in turn facilitate the development of pharmacological and/or behavioral treatments for the disorder in question.
Criteria for an animal model of AUD
There have been reservations as to whether a valid animal model of AUD could be developed (Cicero, 1979; Dole, 1986) . These concerns stemmed from the fact that, in general, animals lower on the evolutionary scale, including rodents, do not readily consume sufficient amounts of ethanol to achieve pharmacologically relevant blood alcohol concentrations (BACs). In order to get a rodent to consume sufficient amounts of ethanol, experimental manipulations are required. These experimental/environmental manipulations include fluid deprivation (Sandi et al., 1990) , schedule-induced polydipsia (Ford, 2014; Meisch, 1975 Meisch, , 2001 , scheduled availability (Holloway et al., 1984) including intermittent everyother-day access (Carnicella et al., 2014) , sucrose-fading (Samson, 1986) , and/or forced induction of dependence (Deutsch and Eisner, 1977) ; which can be achieved intragastrically (Crews, 2008; French, 2001) , intraperitoneally (Pascual et al., 2009 (Pascual et al., , 2014 , by ethanol-vapor exposure (Roberts et al., 2000; Vendruscolo and Roberts, 2014) , chronic drinking of a liquid ethanol diet (Brown et al., 2004; Lieber and DeCarli, 1989) , or long-term drinking with water and food concurrently available ). Most of these methods include an integral stress factor, which does have some face validity with the clinical condition (Al'Absi, 2007) .
Despite the above reservations, certain criteria for an animal model of AUD have been put forth (Cicero, 1979; Dole, 1986; Lester and Freed, 1973) . Briefly, these criteria include 1) the animal should orally self-administer ethanol, 2) the amount of ethanol consumed should result in pharmacologically relevant BACs, 3) ethanol should be consumed for its post-ingestive pharmacological effects, and not strictly for its caloric value or taste, 4) ethanol should be positively reinforcing, such that animals will work for access to ethanol, 5) chronic ethanol consumption should lead to the expression of metabolic and/or functional tolerance, and 6) chronic consumption of ethanol leads to dependence, as indicated by withdrawal symptoms after access to ethanol is terminated. Other criteria have been posited as well. A 7th proposed criterion is the animals should express relapse-like behavior, which manifests as a loss-of-control Rodd et al., 2004b) . Additional criteria might be the ability to display binge-like drinking, as well as the expression of excessive ethanol consumption during the juvenile, adolescent and emerging adult stages of development (e.g., Bell et al., 2013 Bell et al., , 2014 . Finally, with a substantial minority of alcoholics engaging in polysubstance use and abuse, perhaps it is time to include this behavior in criteria for an animal model of AUD (e.g., as well.
Adolescence and emerging adulthood in the rat model
Ethanol use and abuse during adolescence is relatively common around the world (World Health Organization, 2011) . Undoubtedly, some of the reasons may be associated with "rites of passage" such as graduating high school, entering college, joining the military etc. All of these institutions (high school, college, military) often give tacit support for the use and abuse of ethanol. There also is substantial evidence that adolescent mammals have decreased sensitivity to ethanol's perceived negative (e.g., ataxia) effects and increased sensitivity to its perceived positive effects (e.g., behavioral and autonomic activation) (Spear, 2010 (Spear, , 2013 (Spear, , 2014 . Therefore, it is not surprising that adolescent rodents often consume significantly more ethanol than their adult counterparts (Bell et al., 2006c (Bell et al., , 2013 Dhaher et al., 2012a; Spear, 2014) . Research over the years has led to hypothesized parallel ages between humans and rats. These putative time periods (Table 1 adapted from Bell et al., 2013 Bell et al., , 2014 have been based on neurobiological, sexual, foraging, and social characteristics that have been evolutionarily conserved across species (e.g., Spear, 2000 Spear, , 2010 . Table 1 includes relative rat body weights which are the averages of Sprague-Dawley, Wistar, and Long-Evans Hooded rats at their respective ages. Body weights are included because many studies do not list the age of the subjects but do provide body weights. There is still substantial discussion on what constitutes an adolescent or adult rat. For example, Spear (2015) has noted significant differences in the long-term effects of ethanol following early-vs late-adolescent exposure. This parsing of the adolescent window results in some overlap with the juvenile and emerging adulthood stages of development, at least as depicted in Table 1 . Despite this ongoing debate, it is clear that rat models of adolescent substance use and abuse have revealed important information on the behavioral, neurobiological, and genetic consequences of ethanol and/or drug exposure (Adriani and Laviola, 2004; Andersen, 2003; Bell et al., 2013 Bell et al., , 2014 Chambers et al., 2003; Smith, 2003; Spear, 2000 Spear, , 2010 Spear, , 2014 Spear, , 2015 Spear and Varlinskaya, 2006; Witt, 1994 Witt, , 2010 ).
Binge-drinking in rat models
The primary binge-like drinking criteria that can be modeled in the rat are the requirements of (a) BACs greater than 80 mg% and (b) clear signs of intoxication, usually in the form of locomotor impairment. Our laboratory has used three primary behavioral models of binge-like drinking. These are (a) the alcohol deprivation effect (ADE), (b) episodic access, and (c) drinking-in-thedarkdmultiple-scheduled-access (DID-MSA) procedures. The ADE results in both of these parameters being met. The ADE is basically the phenomenon that, after chronic access to ethanol usually 24 h/ day, when ethanol access is terminated and the subjects are reexposed to ethanol access they tend to increase their ethanol intake relative to levels observed before the deprivation interval. However, because the ADE requires extended periods of deprivation before the animal is re-exposed to ethanol access, it probably models relapse-like behavior (Martin-Fardon and Weiss, 2013; Rodd et al., 2004b; Spanagel and Holter, 1999 ) to a greater extent than binge-like drinking. The episodic access procedure is similar to the ADE but incorporates shorter periods of ethanol access and forced abstinence. With the episodic access procedure, rats are given free-choice access to ethanol for an initial 8 days followed by cycles of 4 days of deprivation from and 4 days of re-exposure to ethanol access. Our laboratory has examined the effects of episodic access and found that whereas both high alcohol-drinking 1 and 2, HAD1 and HAD2 replicate lines, rats displayed an escalation of intake (an ADE), alcohol-preferring (P) rats did not . Moreover, this did not appear to be a sex-dependent effect. This episodic protocol has been modified to examine changes in glutamatergic-associated protein levels in the extended Amyg and Acb of adult P rats (Obara et al., 2009) . Overall, these authors reported that expression levels of N-methyl-D-aspartate receptor (GRIN) subunits and Homer proteins were differentially affected by episodic vs continuous access and whether tissue was harvested after a 24 h vs 4-week deprivation period.
The most recent model of binge-like drinking used by our laboratory is the DID-MSA procedure (e.g., Bell et al., 2006b Bell et al., , 2006c Bell et al., , 2011 McBride et al., 2010) . This procedure parallels the DID procedure used in mice (e.g., Boehm et al., 2008; Crabbe et al., 2009; Lyons et al., 2008; Moore and Boehm, 2009; Navarro et al., 2009; Rhodes et al., 2005) . However, initial access to ethanol during the dark-cycle must occur immediately upon lights out to maximize intake in rats, whereas initial access for mice must occur after three or fours into the dark cycle (Bell et al., 2006c; Rhodes et al., 2005 ; but see Colombo et al., 2014) . As with all of the drinking protocols used by our laboratory, water and food are freely available ad libitum. The rats experience between two and four 1 h access periods across the 12 h dark cycle with each access period separated by two or more hours. The rats experience a two day deprivation period each weekend. Selectively bred rats experiencing the DID-MSA procedure readily display BACs in excess of 80 mg%, usually in excess of 100 mg%, with clear signs of motor impairment (e.g., Bell et al., 2011) . When this procedure was adapted for use in operant chambers, P rats displayed BACs in excess of 250 mg% . Finally, it should be noted that limited access scheduling during the rats' active-period (i.e., dark-cycle) has been a procedure used for many years and itself often results in BACs in excess of 80 mg% (See Bell et al., 2014 for a discussion of scheduled ethanol access procedures across 20 þ rat lines/strains).
Selective breeding
Bi-directional selective breeding is a powerful genetic tool that has been employed to study the genetics of many ethanolassociated phenotypes (Crabbe, 2010; Crabbe et al., 2010) . Compared to pure association studies such as genome-wide association studies (GWAS) and studies using recombinant inbred lines (RILs) panels, selective breeding from a heterogeneous outbred stock can make low frequency/rare alleles more common. Selective breeding involves establishing a distribution of scores for the phenotype of interest. Then, subjects are selected from the extremes of this distribution. Subjects from the same extreme are mated together and this cycle of selection and breeding occurs over multiple generations. This results in the high and low off-spring displaying phenotypic extremes that far exceed the range found in the original foundation stock. Heuristically, as relevant genes are segregated correlated traits of the primary selected phenotype (presumably due to pleiotropic actions of genes: Crabbe et al., 1990) can be identified and studied.
Selectively bred high ethanol-consuming rat lines
There are primarily seven bi-directionally selected bred high ethanol-consuming rat lines used globally. The alcohol-preferring AA and alcohol-avoiding [ALKO Non-Alcohol-Accepting (ANA)] rats were developed from a Wistar-Sprague-Dawley cross foundation stock in Helsinki, Finland (Eriksson, 1968) . The lines were revitalized with Brown-Norway and Lewis rat lines in the late 1980's (Sommer et al., 2006) . The high alcohol-drinking HAD and low alcohol-drinking LAD lines of rats were developed from N/NIH heterogeneous stock rats at Indiana University School of Medicine in Indianapolis, Indiana, USA . The N/NIH line of rats was derived from an eight inbred strain cross (ACI, BN, BUF, F344, M520, MR, WKY and WN), with each strain displaying different phenotypes including ethanol intake, at the National Institutes of Health (Hansen and Spuhler, 1984) . Two separate colonies were used to breed HAD and LAD lines of rats, such that replicate (HAD1 vs. LAD1 and HAD2 vs. LAD2) lines are available. The alcoholpreferring, P, and alcohol-nonpreferring, NP, rat lines were developed from closed-colony Wistar foundation stock at the Walter Reed Army Hospital and transferred to the Indiana University School of Medicine in Indianapolis, Indiana, USA (Lumeng et al., 1977) . The Sardinian alcohol-preferring, sP, and alcoholnonpreferring, sNP, rats were developed from a Wistar foundation stock at the University of Cagliari, Italy (Colombo et al., 2006) . The alcohol-preferring UChB and alcohol-nonpreferring [University of Chile A (UChA)] lines of rats were developed from a Wistar foundation stock at the University of Chile, Santiago, Chile (Mardones and Segovia-Riquelme, 1983; Quintanilla et al., 2013) . The Marchigian sP (msP) line does not have a non-preferring counterpart, although an outbred Wistar is often used as a control, and was derived from the sP line from the University of Cagliari, Italy (Ciccocioppo et al., 2006) . The Warsaw High Preferring (WHP) and Warsaw Low Preferring (WLP) rats were developed from a Wistar foundation stock at the Institute of Psychiatry and Neurology, Warszawa, Poland (Bisaga and Kostowski, 1993; Dyr et al., 1999) . All of the above lines were selected for 24 h ethanol intake. A selective breeding program for limited access ethanol intake has also been undertaken yielding the High vs Low Addiction Research Foundation (HARF vs LARF) rat lines (e.g., Le et al., 2001a) .
The 24 h selective breeding programs had two primary selection criteria. First, the high ethanol-consuming rat lines needed to drink at least 5 grams (g) of ethanol/kilogram (kg) bodyweight/day. Five g/kg/day, in a clinical sense, is equivalent to a 165 pound man consuming approximately a fifth of 90-proof whiskey per day. The second criterion is that the animals had to prefer 10% ethanol over water by at least a 2:1 ratio. As seen in Table 2 , all seven high ethanol-consuming rat lines meet the selection criteria and achieve intoxicating BAC levels after free-choice ethanol drinking. Six of the rat lines display an ADE indicating relapse behavior. Six of the rat lines will operantly self-administer ethanol indicating these rat lines find ethanol reinforcing. In addition, six of the lines display behavioral and/or physiological measures (i.e., generally activation or approach behavior) of ethanol reward. Five of the rat lines display tolerance to ethanol-associated effects. In addition, the high drinking lines generally develop quicker, or greater, tolerance to ethanol-associated effects than their low drinking counterparts. Only a few of the rat lines have demonstrated excessive ethanolintake during adolescence, nicotine and/or cocaine selfadministration. Importantly, all seven of the rat lines have published gene differences relative to their low drinking counterparts, or Wistar controls in the case of msP rats.
Other bi-directionally selectively bred rat lines
Other rat lines have undergone selective breeding for endophenotypes associated with AUDs, but were not selected for the high ethanol preference or intake phenotypes. The High Alcohol vs Low Sensitivity (HAS vs LAS) rat lines were selected for ethanolinduced sedation and show alterations in ethanol-induced conditioned taste aversion and nicotine-induced locomotor activity (e.g., de Fiebre et al., 2002; Kulkosky et al., 1995) . The Alcohol Tolerant (AT) and Alcohol Non-Tolerant (ANT) rats were selected for sensitivity to ethanol-induced motor impairment and the development of tolerance to this effect, with non-tolerance being mediated by a mutation of the GABRA-alpha 6 subunit (Wong et al., 1996) . The High Saccharin Consumption (HiS) and Low Saccharin Consumption (LoS) Rats were selected for different propensities to consume a sweet, saccharin solution with the former consuming significantly more ethanol than the latter (c.f., Carroll et al., 2008) . The Taste Aversion Prone (TAP) and Taste Aversion Resistant (TAR) rats were bidirectionally selected for cyclophosphamide conditioned taste aversion (CTA) to a saccharin solution, with the latter showing lower ethanol-induced CTA and greater ethanol intake than the former (e.g., Elkins et al., 1992; Orr et al., 2004) . The Swim Test Susceptible (SUS) and Swim Test Resistant (RES) rats were bidirectionally selected for decreased swimming (SUS) activity when the test was preceded by a stressor, with the latter showing greater ethanol intake than the former (e.g., Weiss et al., 2008) .
Behavioral models for screening treatment compounds and/or targets
The home-cage and operant environments
Home-cage drinking is relatively self-explanatory, such that the rat has access to ethanol in its home-cage environment. There are pros and cons to this test environment and there continues to be a Samson et al., 1998; Toalston et al., 2008; 22 Lumeng and Li, 1986; 23 Gatto et al., 1987; Stewart et al., 1991; 24 Kampov-Polevoy et al., 2000; Waller et al., 1982;  25 Rodd et al., 2003; Rodd-Henricks et al., 2000a , 2000b , 2000c 26 Bell et al., 2003 26 Bell et al., , 2011 26 Bell et al., , 2013 Toalston et al., 2014 Toalston et al., , 2015  27 Hauser et al., 2012a Hauser et al., , 2014a Lê et al., 2006; Rezvani et al., 2010; 28 Katner et al., 2011; Hauser et al., 2014b; Rodd et al., 2007; 29 Bell et al., 2016; McBride et al., 2012 McBride et al., , 2013b 30 Bell et al., 2006a 30 Bell et al., , 2009 30 Bell et al., , 2016 McBride et al., 2010 McBride et al., , 2013a McBride et al., , 2014a McClintick et al., 2015 McClintick et al., , 2016 Obara et al., 2009; Rodd et al., 2008; Sari et al., 2006; 31 Agabio et al., 1996; 32 Colombo et al., 2006; Lobina et al., 1997;  33 Agabio et al., 2001; Colombo et al., 1998b;  34 Vacca et al., 2002a,b; 35 Colombo et al., 2006; 36 Loi et al., 2010; 37 Agabio et al., 2000; Serra et al., 2003; 38 McBride et al., 2012 38 McBride et al., , 2013b  39 Mardones and Segovia-Riquelme, 1983; Quintanilla et al., 2006;  40 Quintanilla et al., 2008; 41 Quintanilla and Tampier, 2011; 42 Quintanilla and Tampier, 2011; Tampier et al., 2008; 43 Tampier and Quintanilla, 2011; 44 Israel et al., 2006; Ocaranza et al., 2008; Quintanilla et al., 2005a Quintanilla et al., , 2005b Quintanilla et al., , 2006 Quintanilla et al., , 2012 debate as to its face validity with the clinical condition. However, home-cage drinking is positively associated with both the reinforcing and rewarding aspects of ethanol (e.g., Green and Grahame, 2008) . On the other hand, operant self-administration requires removing the rat from its home-cage and transporting them to an operant test chamber, which has its own inherent cues, usually in an adjacent room. It is the role of these cues that make operant testing so attractive for compound testing. However, operant testing is resource-intense with greater costs in time, materials, and technicians compared with home-cage testing. Many reviews have been written on operant procedures (June and Gilpin, 2010; Lopez and Becker, 2014; Ostroumov et al., 2015; O'Tousa and Grahame, 2014; Rodd et al., 2004b; Samson and Czachowski, 2003; Vendruscolo and Roberts, 2014; Weiss, 2011) , so only the basics will be covered here. The removal of the animal from their homecage environment, transport to a test room, and placing the animal in the operant chamber results in many opportunities for the animal to form associations between environmental stimuli and learning the reinforcement value of ethanol. Reinforcement refers to the ability of a stimulus to increase the probability of a response occurring in the future, when the stimulus and response have been successfully associated with each other. Positive reinforcement refers to an increased probability of a response, in the presence of a stimulus, in order to receive a "positive" stimulus or reinforcer. Note: that reinforcer is more appropriate than reward because reward is not, in general, dependent upon a trained or conditioned response. Negative reinforcement refers to an increased probability of a response, in the presence of a stimulus, in order to avoid a negative/noxious stimulus. Operant self-administration is conducted in operant chambers, sometimes called Skinner boxes, where a subject is placed in the chamber and allowed to bar press on a lever in order to receive ethanol (the reinforcer). Cues such as lights or sounds, in the chamber, are programmed to alert the animal to different phases of an experiment, such as an anticipation phase before the bar press levers are extend into the chamber. In general, there are two types of schedules-of-reinforcement: ratio which controls the number of responses (usually bar presses) required for reinforcement and interval which controls the period of time at which point the reinforcement is presented following the required response. Fixed-ratio (FR) reinforcement refers to a subject receiving reinforcement after a set number of bar presses. Variable-ratio (VR) reinforcement refers to a subject receiving reinforcement after a random number of responses, with the distribution of these numbers of responses covering a range centered on an average number (i.e., in general this average would be associated with the FR requirement). For instance, an FR-1 schedule would be used to initiate training where the subject receives reinforcement after each bar press. This is also called continuous reinforcement. Similarly, an FR-3 schedule would result in the subject receiving reinforcement after each set of 3 bar presses. Finally, most experimenters include a time-out period following each reinforcement where responses are not counted towards the next reinforcement until the time-out period is over. The time-out is used to control for purely stereotypical behavior (e.g., self-administration of amphetamine which results in stereotypic motor responses that are not explicitly tied to the drug's reinforcement value). Similar to ethanol drinking in the home cage, outbred rats, those not selectively bred for high drinking, require different types of training or shaping regimens in order for the animal to acquire self-administration behavior. This is primarily for the oral route of administration. However, in selectively bred high ethanol-consuming rats this training is minimal or not needed at all indicating these lines find ethanol reinforcing and rewarding (see Table 2 ).
Modeling the stages of the addiction cycle
In general, an ethanol dependent individual develops addiction to ethanol through multiple stages, progressing from impulsive drinking to compulsive drinking (Feltenstein and See, 2013; Koob, 2013; Koob et al., 2014a; Little et al., 2008; Noronha et al., 2014; Olmstead, 2011; Pierce and Kenny, 2013; Scofield et al., 2016; Vanderschuren and Ahmed, 2013) . These stages include acquisition (Carroll and Meisch, 2011) , escalation (Ahmed, 2011) , bingelike behavior (Covington and Miczek, 2011; Stephens et al., 2013) , habit formation and compulsion (Belin et al., 2011; Everitt et al., 2010) , withdrawal (Barr et al., 2011; Koob and LeMoal, 2010) , relapse (Crombag et al., 2010; Erb and Placenza, 2011; Martin-Fardon and Weiss, 2013; Meyerhoff et al., 2013; Stewart, 2010) , craving (Grimm, 2011) , as well as ethanol seeking and a pre-occupation with future use (Lasseter et al., 2010) .
Acquisition of alcohol use disorders
Delaying the onset of ethanol abuse during adolescence and/or emerging adulthood may reduce the risk of developing AUDs later in life. Therefore, treating an individual while they are still engaging in impulsive drinking and before compulsive drinking has been established may prevent the development of ethanol dependence. The closest selectively bred animal model of this would be testing the efficacy of a compound to disrupt acquisition of ethanol intake. This is done by administering the compound concurrently with initial ethanol access, or by pretreating the animal before initial ethanol access. Therefore, disrupting the acquisition of ethanol abuse in today's youth is an important consideration. This would be prophylactic in nature similar to fortifying flour with thiamine to prevent deficiencies and subsequent brain damage and probably restricted to "captive" samples such as those in chemical dependency treatment. Pharmacological studies evaluating the acquisition of ethanol intake have been conducted under both home-cage drinking and operant self-administration conditions. As seen in Table 3 , roles for the adrenergic (Froehlich et al., 2013a,b) , cannabinoid Serra et al., 2001) , GABAergic (GABRB: Colombo et al., 2002a; Orrù et al., 2005) , opioid (Dhaher et al., 2012b; Sable et al., 2006) , and serotonergic (Rodd et al., 2010; Rodd-Henricks et al., 2000a) systems have been implicated in the acquisition of ethanol intake. Of the selectively bred rat lines discussed here, only the P and sP rat lines have been used to examine acquisition of ethanol intake. However, only naltrexone has been tested in both P and sP rats. Unfortunately, all of these treatments had a modest effect on ethanol intake and intake levels increased to control levels after cessation of treatment.
Binge-like drinking
The number of reports documenting pharmacological disruption of binge-like drinking is limited. As discussed above, binge-like drinking is associated with repeated sessions of intoxicated drinking per day (e.g., Bell et al., 2011) . Given this, repeated testing sessions per day precludes controlling for carryover effects. However, most published binge-drinking studies tested the compound either acutely (i.e., once or twice) or chronically on a once-a-day basis. Examples of neurotransmitter systems mediating binge-like intake include the cholinergic (Katner et al., 1997) , dopaminergic , GABAergic (GABRA: Liu et al., 2011) , noradrenergic , and serotonergic ) systems (Table 4) . Of the selectively bred rat lines discussed here, only the AA and P rat lines have been used to examine bingelike drinking, with no compounds being tested in both lines. Unfortunately, since BACs in general were not reported it is difficult to determine if the ethanol intake levels truly met the definition for binge drinking (i.e., >80 mg%).
Maintenance of ethanol drinking
Pharmacological studies examining the maintenance of ethanol drinking have been the test of choice in the ethanol research field. Usually, the assumption is that the maintenance of ethanol intake reflects habitual or compulsive use. In fact, habitual or compulsive use models have been posited as preclinical models for medications testing (Carnicella et al., 2014 ; O'Tousa and Grahame, 2014). Similar to acquisition, studies on maintenance have been performed under both home-cage drinking and operant self-administration conditions. Free-choice access refers to tests during which the animal can choose between ethanol, usually water and food. Sometimes, multiple choices of ethanol solutions are given, which tends to increase the overall volume of intake RoddHenricks et al., 2001 ). The home-cage environment is more amenable to this than the operant chamber. For instance, food is very rarely available in the operant chamber although this could be a control over prandial-associated intake. When assessing the maintenance of ethanol drinking the investigator administers the compound during ongoing drinking. Usually this is done under limited access conditions. The compound is administered and then after a set period of time, usually associated with absorption and the compound's transit of the blood-brain-barrier (BBB), the Tables 1 and 2 for other abbreviations. subject is given access to ethanol for a discrete period-of-time. Limited access is used to assess the acute effects of the compound, especially if tested across days. Although when conducting a study under 24 h access conditions, ethanol intake can be recorded post-treatment at different time-points during the day. This allows the experimenter to measure both the acute (e.g., first 1 h or 4 h post-administration) and more chronic effects of the compound. A benefit of 24 h access tests is the ability to detect the effects of a compound relative to its temporal bioavailability (e.g., absorption, transit across the BBB, and metabolism). An interpretative difficulty of 24 h access testing is the inability to disentangle the interactional post-acute compound effects from continuous ethanol intake effects, although limited access tests also have this problem but to a lesser degree. Major concurrent measures would include body weight as well as food and water intake to detect secondary effects. Examples of neurotransmitters modulating the maintenance of ethanol intake include the adrenergic (alpha: Froehlich et al., 2013a) , cannabinoid Gessa et al., 2005; Hansson et al., 2007) , cholinergic (Bell et al., 2009a; Sotomayor-Zarate et al., 2013) , dopaminergic (Dyr et al., 1993; Thanos et al., 2005) , GABAergic (GABRA: Agabio et al., 1998; GABRA-BDZ complex: June et al., 1998b; McKay et al., 2004; GABRB: Maccioni et al., 2012; Quintanilla et al., 2008) , glutamatergic Cowen et al., 2005b; Sari et al., 2013a) , histaminergic (Lintunen et al., 2001) , opioid (pan-opioid: Hyyti€ a and Sinclair, 1993; June et al., 1998d; MOR: Honkanen et al., 1996; Krishnan-Sarin et al., 1998; DOR: Hyyti€ a and Kiianmaa, 2001; sigma: Sabino et al., 2009a) , and serotonergic (Long et al., 1996; Overstreet et al., 1997; Panocka et al., 1995b; West et al., 2011) systems (Table 5) . Overall, the neurotransmitter systems most often tested across the lines have been the (a) cannabinoid system in six of the selectively bred rat lines, (b) GABAergic system in five of the selectively bred lines as well as Sprague-Dawley and Long-Evans Hooded outbred lines, and (c) opioid system in six of the selectively bred rat lines as well as Sprague-Dawley and Wistar outbred lines. Across the rat lines, the CB1R antagonist, SR-141716, has been tested in six of the selectively bred rat lines as well as Wistar rats with consistent reductions in ethanol intake. Across rat lines, naloxone/naltrexone has been tested in, and consistently reduced ethanol intake by, five of the selectively bred rat lines as well as Sprague-Dawley and Wistar rats.
Relapse behavior
Ethanol abuse and dependence are considered chronic relapsing disorders, such that 60e80 percent of abstinent alcoholics will relapse during their lifetime (Barrick and Connors, 2002; Chiauzzi, 1991; Jaffe, 2002; Weiss, 2011) . Thus, an animal model of AUD ought to demonstrate this feature of the clinical picture as well . Although a number of criteria for relapse have been put forth (Barrick and Connors, 2002; Chiauzzi, 1991; Jaffe, 2002; Weiss, 2011) , the primary criterion holds that a return to levels of ethanol consumption equal to or greater than that observed prior to abstinence constitutes a relapse. A common model of AUD relapse is the alcohol deprivation effect (ADE). The ADE is a temporary increase in ethanol intake and/or preference over water upon re-exposure to ethanol access compared with levels observed prior to ethanol withdrawal (Brown et al., 1998; Burish et al., 1981; Heyser et al., 1997 Heyser et al., , 2003 Kornet et al., 1990; McKinzie et al., 1998; Mello and Mendelson, 1972; Rodd et al., 2003; Rodd-Henricks et al., 2000a Sinclair, 1971; Sinclair and Li, 1989; Sinclair and Senter, 1967; Sinclair et al., 1973; Wolffgramm and Heyne, 1995) . Thus, by definition the ADE usually reflects an escalation of intake. Moreover, the ADE is not simply an effect of withdrawal, because it can be observed before an animal becomes physically dependent upon ethanol ; McKinzie Rodd-Henricks et al., 2000a Sinclair and Senter, 1967) or after overt withdrawal signs have passed (Rodd-Henricks et al., 2002a; Rodd et al., 2003) . While most studies have relied upon a single period of abstinence, this does not parallel the clinical condition because most individuals seeking treatment have experienced multiple cycles of abstinence and relapse. Finally, as seen in Table 2 , different selectively bred rat lines display different ADE profiles (e.g., time-dependent) under particular conditions. Given the multiple genes, each contributing a relatively small effect-size, mediating the genetic risk for developing AUD; it is not surprising that there are different drinking, including relapse, profiles among the selected lines (Table 2) . Examples of neurotransmitters and neuromodulators modulating relapse to ethanol intake include the adrenergic (alpha: Froehlich et al., 2013a) , cannabinoid Gessa et al., 2005; Hansson et al., 2007) , cholinergic (Bell et al., 2009a; Sotomayor-Zarate et al., 2013) , dopaminergic (Dyr et al., 1993; Thanos et al., 2005) , GABAergic (GABRA: Agabio et al., 1998; GABRA-BDZ complex: June et al., 1998b; McKay et al., 2004; GABRB: Maccioni et al., 2012; Quintanilla et al., 2008) , glutamatergic Cowen et al., 2005b; Sari et al., 2013a) , histaminergic (Lintunen et al., 2001) , opioid (pan-opioid: Hyyti€ a and Sinclair, 1993; June et al., 1998d; MOR: Honkanen et al., 1996; Krishnan-Sarin et al., 1998; DOR: Hyyti€ a and Kiianmaa, 2001; Sigma: Sabino et al., 2009a) , and serotonergic (Long et al., 1996; Overstreet et al., 1997; Panocka et al., 1995b; West et al., 2011 ) systems (Table 6) . Unfortunately, only the P, HAD1, HAD2, and sP rat lines have been consistently used to assess compound efficacy in disrupting relapse-like behavior. Moreover, no single compound has been tested across three or more selectively bred rat lines. Thus, more research is needed to address the validity of findings across selectively bred rat lines and/or mouse lines.
Ethanol-seeking (craving) behavior
For the present discussion, craving and ethanol-seeking will be considered similar constructs on a behavioral continuum from a more visceral response to an overt behavioral response, respectively. To test for ethanol-seeking behavior, an animal is trained to operantly self-administer ethanol, this operant response is then extinguished, such that the animal no longer responds on the lever previously associated with ethanol reinforcement, with changes in response rate across time reflecting seeking behavior. This can also be determined by comparing response numbers between the lever previously associated with ethanol and the control lever (i.e., is the animal able to distinguish between the two). Or, another method would be to compare the response rate with a baseline rate recorded prior to extinction. It has been suggested that the rate of extinction can be a measure of ethanol-seeking, because the animal continues to manifest an overt behavior directed toward the lever previously associated with ethanol reinforcement in the absence of reinforcement Littleton, 2000) . In a clinical sense, this would be similar to an individual displaying approach behavior (i.e., going to the liquor store) and being frustrated by the fact that Responses on the operant lever, previously associated with ethanol reinforcement, in the absence of reinforcement can be elicited several ways. Here we will examine (a) drug-induced "priming" of the response, (b) cue-induced "priming" of the response, and (c) "Pavlovian Spontaneous Recovery" (PSR) of the response. Essentially, PSR stems from the work of Pavlov who showed that simply returning the animal to the environment previously associated with reinforcement "recovered" the response, even if the response was absent (i.e., extinguished) at the end of the previous session (c.f., Rodd et al., 2004b) . All of these methods have been reviewed by others as noted in sections 4.1 and 4.2 and the present discussion will only present an overview. The word priming is used because these three methods essentially prepare/prime the animal to make the response. These three forms of reinstatement of responding can be arranged on a continuum from the most overt (drug-induced priming) to the least overt (PSR), in the sense that all three use cues to elicit the response. Drug-induced priming automatically incorporates environmental cues associated with (a) drug self-administration as well as (b) drug-induced physiological responses. The drug-induced priming dose is usually too small to induce behavioral activation. Nevertheless, most drugs-of-abuse, including ethanol, do sensitize behavioral activation (i.e., shift the dose-response curve to the left) and; therefore, this remains a critique of this model/procedure.
Cue-induced priming of the response uses discrete cues from the environment that were previously associated with ethanol selfadministration . Therefore, the environmental cues recruited in drug-induced priming are also present in cue-induced priming but overt physiological responses to the drug are absent. The role of environmental cues in drug-vs cue-induced priming can, to some degree, be dissociated by administering the drug priming in a different environment. However, absolute dissociation is impossible. Finally, PSR of responding incorporates the environmental cues used in cue-induced priming. One method to dissociate the more subtle cues in the environment from the more overt, discrete cues used in cue-induced priming is to employ positive (þ), negative (À) and neutral cues in the methodology. (þ)-cues are stimuli previously associated with ethanol/drug availability, (À)-cues are stimuli previously associated with ethanol/drug "non"-availability, and neutral cues are environmental cues present in both circumstances (e.g., Knight et al., 2016) . As seen in Table 7 , roles for the adrenergic (alpha: Bertholomey et al., 2013) , cannabinoid (Cippitelli et al., 2005) , cholinergic (Hauser et al., 2014a; Le et al., 2003) , dopaminergic (Hauser et al., 2014b; Vengeliene et al., 2006) , GABAergic (GABRB: Maccioni et al., 2008b) , glutamatergic Rodd et al., 2006; von der Goltz et al., 2009 ), neuropeptide Y (Bertholomey et al., 2011 , nociceptin-orphanin (Ciccocioppo et al., 2004) , opioid (pan-opioid: Le et al., 1999; MOR: Giuliano et al., 2015; DOR: HendersonRedmond and Czachowski, 2014; KOR: Deehan et al., 2012) , and serotonergic (Hauser et al., 2014a) systems have been implicated in ethanol-seeking and -craving behavior. Also as seen in Table 7 , outbred rat lines are used more consistently than selectively bred rat lines when investigating the efficacy of compounds to disrupt ethanol-craving and eseeking behavior.
Dependence and withdrawal-associated effects
The research on dependence and withdrawal in rats has been limited, at least as it pertains to medications screening for the treatment of AUD. Early work examined the GABAergic system, due to the fact that agonists of this system were, and still are, used to treat the danger of ethanol-withdrawal associated seizures. Subsequent work examined the role of the glutamatergic system and its hyperexcitability in the dependent state. This paralleled work examining neurosteroids and their modulation of the GABAergic system. Peptide systems such as cotricotrophin releasing factor (CRF) and neuropeptide Y (NPY) have also received attention because of their recognized role in anxiety and their activity in the extended amygdala. More recent research has recognized that stress-associated systems play a key role in the development and maintenance of AUD and addiction in which withdrawal plays an important part (See Griffin, 2014; Hopf et al., 2011) . Therefore, stress-associated seeking and/or craving behavior has received research interest but mostly in non-selectively bred (i.e., outbred) rat lines. Table 8 describes some of the neurotransmitters and neuromodulators mediating stress-associated findings from selectively bred and outbred rats. These include the adrenergic (Rasmussen et al., 2014) , corticotrophin (Overstreet et al., 2007) , dopaminergic (Overstreet et al., 2007) , GABAergic (GABRA-BDZ: Knapp et al., 2007a Knapp et al., , 2007b , neuroimmune (Breese et al., 2008) , neuropeptide Y (Cippitelli et al., 2011) , and serotonergic (Overstreet et al., 2007) systems.
Summary
The research presented in Tables 3 through 8 highlights compounds and rat lines used to assess disruption of different stages in the addiction cycle. The tables were tabulated to provide a historical perspective on the evolution of (a) neurotransmitter/neuromodulatory targets examined as well as (b) stages in the addiction cycle being investigated. Although this paper has focused primarily on selectively bred rat lines, it has included some of the findings garnered from research using outbred rat lines. This provides some context into which the results from selectively bred rat research can be placed. This also highlights some areas of medications screening that have been dominated by the use of outbred rat lines. A very clear example of this is the dependence/withdrawal/stress areas of research. This is due, at least in part, to the fact that the active selection process has resulted in high ethanol-consuming rats that can consume ethanol with limited adverse effects. From the data presented herein and a previous paper , it is clear that not all neurotransmitter/neuromodulatory systems have received the same level of scrutiny in all of the rat lines. For instance, the vast majority of the research examining the alcohol dehydrogenase and aldehyde dehydrogenase systems has been performed in the UChB and UChA rat lines. Similarly, histaminergic research has been limited to the AA and ANA rat lines. Another example is the cannabinoid system, such that most of the research in these selected rat lines has been conducted in the sP and sNP rat lines, with the AA and ANA rat lines also receiving substantial focus.
This uneven focus, across the rat lines, on particular neurotransmitter systems creates difficulty with interpreting validity. Exacerbating this is the fact that the present publishing environment places low priority on negative findings and if a particular compound is found to be effective in one rat line it is rarely tested in the other rat lines. Reasoning for the latter is that studies following the first one are not novel. In order to increase the validity of animal research targeting treatment of AUDs, the field needs to understand both the positive and negative findings for particular compound classes (e.g., neurotransmitter, neuromodulator, transcription factor, etc.) and/or compounds within a class. Finally, the present review makes it clear that the single neurotransmitter/ neuromodulatory-system research approach that characterized early work has progressed to a more thorough understanding of intracellular cascades that are involved in multiple neuromodulatory systems. In addition, it also is now recognized, with some of these findings presented in their respective Tables, that neurotransmitter/neuromodulatory systems involved in one stage of the addiction cycle do not necessarily mediate another stage of the addiction cycle.
Caveats, challenges, and conclusions
A few caveats need to be mentioned before summarizing this review. First, the mouse ethanol research literature was not discussed. This was done due to space limitations and in no way minimizes the substantial literature that is associated with it. Second, transgenic ethanol research was not discussed. Similar to the first caveat, especially since most of the transgenic work has involved mice, this was done due to space limitations. For excellent discussions on both of these subjects see Barkley-Levenson and Crabbe (2014) , Bilbao (2013) , Crabbe et al. (2006) , Fisch and Flint (2006) , Greenberg and Crabbe (2016) , Kalueff and Bergner (2010) , Mayfield et al. (2016) , as well as Oberlin et al. (2011) . Third, models of withdrawal, and to some degree dependence, as well as stress and its associated medications screening received limited review. To a great extent this is also related to the first caveat, in the sense that most of the ethanol withdrawal research has been conducted in mice. We noted some of the rat research, often using outbred rat lines, in section 4.8 and Table 8 ; for other work and discussion see Al'Absi (2007) , Becker (2013) , Burke and Miczek (2014) , Greenberg and Crabbe (2016) , Lopez and Becker (2014) , Metten et al. (2014) , Phillips et al. (2015) , Spanagel et al. (2014a) , Vendruscolo and Roberts (2014) , as well as Zorrilla et al. (2014) .
This review highlights the fact that most of the medications research conducted thus far has sought to delineate the role and importance of different neuromodulatory and neuroanatomical systems in the maintenance of ethanol intake. This is especially obvious from the early ethanol research focus on the role of the opioid, dopaminergic, and serotonergic systems in ethanol abuse and dependence. Of these systems, the most effective FDAapproved medication (naltrexone) targets the opioid system. As outlined elsewhere (e.g., Bell et al., 2012) , the bi-directional selection for high vs low ethanol-consuming rat lines has resulted in dopaminergic and serotonergic deficits in many, but not all of the high ethanol-consuming rat lines. Therefore, it is not surprising that much of the earlier research focused on these neurotransmitter systems. However, much of this earlier, and later, work did not result in readily translatable treatment strategies. Recognition of the difficulty in translating preclinical findings into clinical treatments has been recognized by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH). To facilitate testing compound efficacy, NIAAA and NIDA have created programs, in partnership with the pharmaceutical industry, to screen compounds that have either received FDA-approval for other indications or have gone through significant clinical trials. Essentially, the objective is to assess the ability to "repurpose" drugs to treat AUDs that have already received considerable regulatory scrutiny.
The National Institute on Mental Health (NIMH) of NIH has also recognized this modest translatability of preclinical research to clinical practice and has developed, as well as incorporated, the Research Domain Criteria (RDoC) program into their preclinical funding strategies. RDoC incorporates examination of the psychobiological and neuroscientific causation into translational research models. Put another way, RDoC focuses on dimensional/valence constructs observed across multiple mental disorders rather than strict diagnostic symptomology related to a single disorder (Cuthbert, 2016; Kozak and Cuthbert, 2016; MacNamara and Phan, 2016) . This focus on systems, rather than clinical diagnostic symptoms, has seemingly pitted the RDoC project against the Diagnostic and Statistical Manual of Mental Disorders system (e.g., Pritchard, 2015) , such that a binary (i.e., one-or-the-other) system approach is generally discouraged (Shorter, 2015) . As noted by Kaffman and Krystal (2012) and from the work of Hyman and colleagues (Hyman, 2010; Casey et al., 2013) , the DSM and ICD classification systems were developed to achieve the highest interrater reliability based on diagnostic symptomology. Therefore, animal models of psychiatric disorders have generally focused on recapitulating many if not all of the DSM-and ICD-defined symptoms as separate models. However, this focus on diagnostic symptomology has, to some degree, interfered with recognizing that there are domains of symptomology stretching across different diagnostic categories. NIMH, NIAAA, and NIDA have recognized this and have developed several joint funding programs that recognize that, for instance, ethanol, nicotine, and stimulant addiction are not unitary phenomenon with minimal overlap. Rather, ethanol dependence has to be examined within its neurobiological, physiological, developmental, behavioral, and social context (c.f., Kaffman and Krystal, 2012; Kobeissy, 2012; Nestler and Hyman, 2010) .
With these considerations in mind, the present paper first presented a background from a clinical perspective in order to provide an overview of the constellation of factors influencing the development of ethanol dependence in humans. Section two provided some background on the rat and how the above clinical factors can be examined within the rat's developmental context. For instance, rats also go through developmental stages and physiological as well as behavioral milestones point to adolescence as a critical stage of development for rats just as it is for humans. Also, binge eating and drinking are observed in adolescent rats just as they are in humans. Moreover, rats display physiological characteristics of lower sensitivity to ethanol's aversive, but not necessarily deleterious, effects and higher sensitivity to ethanol's stimulating effects similar to observations in the clinical setting. Thus through experimental manipulations, it has been shown that binge ethanol intake by adolescent rats is not purely to satisfy increased caloric demand associated with the adolescent growth spurt. The third section highlighted behavioral characteristics of the seven dominant selectively bred high, vs low, ethanolconsuming rat lines in the world. As shown in Table 2 , all of the lines display many of the characteristics observed in individuals caught in the ethanol addiction cycle.
The fourth section discussed common pharmacological test procedures as they relate to stages of the addiction cycle. Each of these stages is accompanied by a table highlighting associated findings from the seven, international selectively bred high ethanol-consuming rat lines as well as some findings from other selectively bred rat lines and outbred rats. Overall, the literature Breese et al., 2008 See Tables 1 through 7 for abbreviations. reviewed herein indicates that all of these high ethanol-consuming rat lines have face validity displaying many, but not necessarily all, of the characteristics observed in the ethanol-dependent individual. In addition, each of the lines has tested various neurotransmitter and neuromodulator compounds in the procedures outlined in the fourth section. Nevertheless, these animal models need to be expanded into more holistic models. For instance, binge-drinking with an adolescent age-of-onset is a crucial factor in the development of AUDs that has received limited attention. In addition, most individuals addicted to ethanol are also addicted to other substances-of-abuse and discussions regarding animal models of polysubstance dependence are limited. Therefore, despite making progress in determining the neurobiological systems mediating ethanol dependence, further work using more holistic models needs to be undertaken in both the preclinical and clinical areas to determine molecular targets for pharmacological treatment of AUDs.
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